Caliway Biopharmaceuticals Co. L
TAI: 6919.TW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Vivian Ling
- Headquarters
- New Taipei City, Taiwan
- IPO year
- 2022
- Market cap
- NT$161.9B
- Website
- https://www.caliway.com.tw
Loading 6919…
Loading profile data…Frequently asked questions about 6919
What does Caliway Biopharmaceuticals Co. L (6919.TW) do?
Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment. It is also de...
Where does 6919.TW trade?
Caliway Biopharmaceuticals Co. L (6919.TW) trades on the Taiwan Stock Exchange.
What sector is 6919.TW in?
Caliway Biopharmaceuticals Co. L (6919.TW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Caliway Biopharmaceuticals Co. L?
Vivian Ling is the chief executive officer of Caliway Biopharmaceuticals Co. L (6919.TW).
Where is Caliway Biopharmaceuticals Co. L headquartered?
Caliway Biopharmaceuticals Co. L is headquartered in Taiwan.
Does 6919.TW pay a dividend?
Caliway Biopharmaceuticals Co. L (6919.TW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6919.TW go public?
Caliway Biopharmaceuticals Co. L (6919.TW) completed its initial public offering in 2022.